AstraZeneca CEO on Cancer Treatment, Covid in China

The transcript covers AstraZeneca's business growth, highlighting a 60% growth rate despite COVID-19 challenges affecting cancer diagnosis and treatment. The discussion shifts to the oversupply of COVID vaccines and the focus on Evershed, a product for immunocompromised individuals. Future plans include developing antibodies for other infections and addressing the impact of COVID lockdowns in China on business operations. The CEO discusses China's innovation and leadership, and touches on succession planning within AstraZeneca, emphasizing the exciting opportunities in the industry.

How does the speaker assess the impact of lockdowns in China on their business?

What is the speaker's view on President Xi Jinping's leadership?

What is the speaker's stance on succession planning at AstraZeneca?